A consolidated US healthcare reform proposal issued by President Barack Obama suggests increasing an annual tax to be imposed on the research-based pharmaceutical industry from $23 billion over ten years, as proposed by Congress, to $33 billion1,2.
The proposal would also delay the implementation of these fees by one year, until 2011, and would make changes to facilitate the fee’s administration by the Internal Revenue Service...
Please login to read the full article.
